Agent | Level of evidence | Basis for evidence |
Natalizumab | Strong | Rare definite cases in clinical trials |
Rituximab | Uncertain | Rare definite cases outside clinical trials |
TNF inhibitors | Uncertain* | No definite cases |
Abatacept | None | – |
*This may be under-reported.13
TNF, tumour necrosis factor.